Table 1 Patient and disease characteristics at start of etanercept therapy ^a

Females, n (%)

36 (54)

Age at onset JIA in years, mean (±SD)

8.5 (±3.8)

Age at start etanercept in years, mean (±SD)

11.0 (±3.1)

JIA disease duration before start etanercept in years, median (IQR)

1.8 (1.1 to 3.8)

ANA-positive, n (%)

14 (21)

Category JIA, n (%)

Systemic JIA

4 (6)

Polyarticular RF-negative

27 (40)

Polyarticular RF-positive

9 (13)

Oligoarticular extended

18 (27)

Psoriatic arthritis

5 (8)

Enthesitis-related arthritis

4 (6)

Previously used medications, n (%)

Systemic prednisone

32 (48)

Methotrexate

66 (99)

DMARD other than MTX

14 (21)

Concomitant comedication at start of biologic therapy, n (%)

Systemic prednisone

26 (39)

Methotrexate

64 (96)

DMARD other than MTX

2 (3)

Disease activity parameters at baseline, median (IQR)

Physician-rated VAS (0 to 10 cm; best score = 0)

6.5 (5.0 to 7.4)

CHAQ total (0 to 3; best score = 0)

1.50 (0.90 to 2.10)

VAS pain (0 to 10 cm; best score = 0)

6.3 (2.4 to 7.7)

VAS well-being (0 to 10 cm; best score = 0)

6.1 (3.2 to 7.4)

Active joints

11 (7 to 18)

Limited joints

6 (3 to 13)

ESR

11 (5 to 29)

JADAS-10 (0 to 40), mean (±SD)

21 (±5)

Ever hand or wrist involvement, n (%)

64 (96)

Z-score of BA, mean (±SD)

-0.36 (±1.44)

Z-score of BHI, mean (±SD)

-0.85 (±1.15)^b